As a potential treatment of COVID-19: Montelukast

Página do item simplificado
dc.creatorFidan, Cihan
dc.creatorAydoğdu, Ayşe
dc.date.accessioned2020-07-03T20:04:57Z
dc.date.available2020-07-03T20:04:57Z
dc.date.issued2020-09
dc.description.abstractIt has been hypothesized that Montelukast, a cysteinyl leukotriene (cysLT) receptor antagonist, with effects of anti-inflammatory, suppress oxidative stress and reduce affect cytokine production, may limited progression of the disease on COVID-19 infection.pt_BR
dc.identifier.citationFIDAN, C.; AYDOĞDU, A. As a potential treatment of COVID-19: Montelukast. Medical Hypotheses, [S.l.], v. 142, Sept. 2020.pt_BR
dc.identifier.urihttps://repositorio.ufla.br/handle/1/41712
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0306987720306368pt_BR
dc.languageen_USpt_BR
dc.publisherElsevierpt_BR
dc.rightsopenAccesspt_BR
dc.sourceMedical Hypothesespt_BR
dc.titleAs a potential treatment of COVID-19: Montelukastpt_BR
dc.typeArtigopt_BR

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
license.txt
Tamanho:
953 B
Formato:
Item-specific license agreed upon to submission
Descrição:
Baixar

Coleções

FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)